Vivos Therapeutics Inc. (VVOS): Price and Financial Metrics


Vivos Therapeutics Inc. (VVOS): $1.22

-0.07 (-5.43%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

VVOS Stock Price Chart Interactive Chart >

Price chart for VVOS

VVOS Price/Volume Stats

Current price $1.22 52-week high $7.09
Prev. close $1.29 52-week low $1.11
Day low $1.16 Volume 29,200
Day high $1.28 Avg. volume 1,128,982
50-day MA $1.58 Dividend yield N/A
200-day MA $2.60 Market Cap 28.07M

Vivos Therapeutics Inc. (VVOS) Company Bio


Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of technology solutions for patients with sleep disordered breathing (SDB) comprising mild-to-moderate obstructive sleep apnea (OSA). The company's solutions cover proprietary alternatives for treating mild-to-moderate OSA; craniofacial and anatomical anomalies that are associated with mild-to-moderate OSA. Its treatment for OSA involves specially designed and customized oral appliances and treatment protocols. The company, through its Vivos Integrated Healthcare Network, provides access to healthcare providers for delivering care for patients suffering from sleep disordered breathing, including mild-to-moderate OSA. Vivos Therapeutics, Inc. also licenses its intellectual property to third-party manufacturers, which fabricate appliance devices for healthcare professionals. It caters to general dentists, medical doctors, myofunctional therapists, chiropractors, healthcare providers, and patients in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2007 and is based in Highlands Ranch, Colorado.


VVOS Latest News Stream


Event/Time News Detail
Loading, please wait...

VVOS Latest Social Stream


Loading social stream, please wait...

View Full VVOS Social Stream

Latest VVOS News From Around the Web

Below are the latest news stories about Vivos Therapeutics Inc that investors may wish to consider to help them evaluate VVOS as an investment opportunity.

Vivos Therapeutics to Present at March 2022 World Sleep Congress in Rome

Vivos Medical Advisory Board to Expound on Clinical Data Set of Improved Patient Outcomes at One of the World’s Largest Sleep ConferencesHIGHLANDS RANCH, Colo., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring in adults, today announced that

Yahoo | February 24, 2022

Vivos Therapeutics Files for US Patent on Proprietary New Clinical Protocols After Seeing Further Significant Improvement in Reduction of Key Sleep Apnea Metric

Vivos’ Continuous Clinical Improvement Program Yields Promising Data in AHI Score Reductions for Patients with Obstructive Sleep ApneaHIGHLANDS RANCH, Colo., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring, today announced the filing of a U.

Yahoo | January 27, 2022

Hot Penny Stocks: What’s Moving VVOS, GMDA and SBEV Higher Today?

Several penny stocks are on the move Wednesday and we're diving into the hot news behind that momentum with a quick dive into the space.

William White on InvestorPlace | January 19, 2022

Vivos Therapeutics Announces 18X Increase in Sleep Apnea Diagnostic Testing By Vivos Dentists Using SleepImage Technology

Vivos Also Announces Improved Pricing Agreement With SleepImage Dentists and Patients Report Exceptional User Experience with SleepImage Home Sleep Test HIGHLANDS RANCH, Colo., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . ("Vivos" or "the Company") (NASDAQ: VVOS ), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring, today announced significant increases across several key metrics for its SleepImage Home Sleep Apnea Tests (HST). In particular, for the three-months ended December 31, 2021, versus the three-months ended December 31, 2020, Vivos reported: an 18 times increase in the total number of HSTs given across the netw...

Benzinga | January 19, 2022

Zogenix, Vivos lead healthcare gainers; Cardiff Oncology, Yumanity among losers

Zogenix ZGNX +68%. Vivos Therapeutics VVOS +33%. Cardiff Oncology CRDF -24%. Yumanity Therapeutics YMTX -17%.

Seeking Alpha | January 19, 2022

Read More 'VVOS' Stories Here

VVOS Price Returns

1-mo -35.79%
3-mo -33.33%
6-mo -42.45%
1-year -72.95%
3-year N/A
5-year N/A
YTD -45.78%
2021 -61.93%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6326 seconds.